NEWCASTLE UPON TYNE, UK, Dec 17 (Bernama-GLOBE NEWSWIRE) —QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over £11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC™ and disposable test cassette.
QuantuMDx accelerated development, scale-up and manufacture of Q-POC™ – its rapid point-of-care testing system – earlier this year in response to the COVID-19 pandemic.